Exhibit 99.1 Esperion Provides Business Update at 44 Annual J.P. Morgan Healthcare Conference th – Reports $156 to$160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – "By 2040, we envision Esperion as a company with multiple blockbuster products on the market, a robust pipeline of next-generation therapies, and a proven commercial infrastructure that makes us a partner of choice. Our deep expertise in ACLY biology and our relentless focus ...